Alpha Compute Corp · NASDAQ:ALP
Alpha Compute — Portage Biotech — Investor Presentation (November 2023)
24 slides from Alpha Compute's investor presentation, Nov 13, 2023
Slide 1: Corporate Presentation
1 Corporate Presentation Nasdaq: PRTG November 2023
Slide 2: Legal Disclaimer
2 Legal Disclaimer Forward - Looking Information This presentation contains "forward - looking statements" that involve risks and uncertainties . Our actual results could differ materially from those discussed in the forward - looking statements . The statements contained in this presentation that a
Slide 3: Immuno-Oncology Company with Four First/Best in Class Compounds in the Clinic
3 Immuno - Oncology Company with Four First/Best in Class Compounds in the Clinic Investment Highlights Cost - Efficient Business Model Multiple Data Catalysts in 2023 and 2024 Experienced Leadership Team from Bristol Myers Squibb
Slide 4: Proven Leadership with Oncology and Financing Expertise
4 Allan Shaw CFO Justin Fairchild VP Clin Dev Proven Leadership with Oncology and Financing Expertise Board of Directors Gregory Bailey, MD Rob Glassman, MD Linda M. Kozick Jim Mellon Mark Simon Ian Walters, MD CEO, Chairman Rob Kramer, PhD CSO Steve Innaimo VP PM & Operations Brian Wiley CBO Steven
Slide 5: Our Formula for Success
5 Our Formula for Success De - Risked Development Structured to Create Significant Value Strong Academic & Industry Network First/Best in Class I/O Agents Potential for Large Returns • Compounds with broad targets, single agent activity • Address ~70 - 80% of patients that don’t respond • Randomized
Slide 6: Nine Phase 1b/2 Data Catalysts Anticipated to Drive Value
6 Nine Phase 1b/2 Data Catalysts Anticipated to Drive Value iNKT Engager Platform Adenosine Plat Final Data Interim Data # of PTS STAGE INDICATION ASSET Q1 2024 ASCO 2023 18 Phase 1 Melanoma + NSCLC PORT - 2 13 Phase 1^ Solid Tumors PORT - 3 IST ASCO 2025 SITC 2024 10 Phase 2* Refractory Melanoma PO
Slide 7: iNKT Engagers PORT-2, PORT-3
iNKT Engagers PORT - 2, PORT - 3 Activating the innate, adaptive immune system and correcting the tumor microenvironment
Slide 8: Portage's iNKT Engager (PORT-2): Rationally Designed Liposomal Formulation of IMM60
8 Portage’s iNKT Engager (PORT - 2): Rationally Designed Liposomal Formulation of IMM60 iNKT cell iNKT in charged liposome to protect lipid chain, aggregate in tumor, and promote Type 1 cytokine release IMM60 Binds to CD1d on APC and other myeloid cells TCR CD1d PORT 2 Immune activation
Slide 9: PORT-2 Stimulates Multiple Arms of the Immune System
9 Innate Immune System: Adaptive Immune System: Tumor Microenvironment: Kills cancer cells & increased PD - L1 expression iNKT cell PORT - 2 Stimulates Multiple Arms of the Immune System to Produce a Robust Anti - Cancer Response
Slide 10: Multiple Cell Types Needed for Anti-Cancer Response
10 Antigen MDSC & TAM CD - 8 T cell B - cell Dendritic cell NK cell Target cells Companies in the space PD - 1 PD - L1 Tumor Cell • Upregulates PD - L1 • Monotherapy activity in PD - 1 resistant models • Combo restores sensitivity to PD - 1 Ab + Enhanced activation Multiple Cell Types Needed for Ant
Slide 11: PORT-2 Demonstrates Robust Pre-Clinical Single Agent Activity
11 PORT - 2 Demonstrates Robust Pre - Clinical Single Agent Activity Jukes et al Eur. J. Immunol. 2016. 00: 1 – 11 IMM60 (0.5ng/mouse) PORT - 2 Vehicle + anti PD - 1 Vehicle Untreated PORT - 2 shows better response rates vs. anti - PD - 1 in melanoma model B16 melanoma lung metastases
Slide 12: SITC 2023 Data Further Supports PORT-2 Favorable Safety & Tolerability Profile
12 SITC 2023 Data Further Supports PORT - 2 Favorable Safety & Tolerability Profile At All Doses Tested to Date Safety • No DLT’s, related SAEs, or G3 - 5 related AEs • Only G1 related AEs have been observed at the highest dose of PORT - 2 • Patient treated with PORT - 2 + pembrolizumab(n=2) experie
Slide 13: SITC 2023 - Early Evidence of Single Agent Activity for PORT-2
13 SITC 2023 - Early Evidence of Single Agent Activity for PORT - 2 in Advanced Melanoma & NSCLC Single agent activity observed in select target lesions • Serum biomarker analyses provide evidence of iNKT, NK, DC activation, as well as increases in antigen - presenting CD86+ B cells following treatm
Slide 14: IMPORT-201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma
14 Multi - arm study with four parallel development paths = multiple shots on goal IMPORT - 201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma* https://www.isrctn.com/ISRCTN80472712 . * Planned depending data and available liquidity PD - 1 q3wk iv infusions n=15 PD - 1 naïve patients PO
Slide 15: Adenosine Portfolio
Adenosine Portfolio Validated mechanism impacting multiple immune cells Opportunity to modulate adenosine in 4 different ways: PORT - 6 A2AR Antagonist PORT - 7 A2BR Antagonist PORT - 8 A2AR/A2BR Dual Antagonist PORT - 9 Gut - Restricted A2BR Antagonist
Slide 16: Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment
16 Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment Targeting Adenosine in Cancer Immunotherapy to Enhance T - Cell Function; Virgano, et al; Frontiers in Immunology 2019 modified slightly and used under CC BY 4.0 Macrophage Treg T cell NK Cell Endothelial Cell CAF MDSC
Slide 17: Difference in A2A Small Molecules
17 Difference in A2A Small Molecules 10+ hrs Only asset to demonstrate single agent activity in mouse models Competitive inhibitors won’t block in settings of high adenosine ARCUS CORVUS Potency Selectivity 2.5 hrs Portage’s PORT - 6 is best in class for potency, selectivity and durability* Relative
Slide 18: Fast Follower with Precedent for Biomarker Selection
18 Fast Follower with Precedent for Biomarker Selection * Expression data from Labcorp % A2A high* Tumor type 50 RCC 38 BC 34 NSCLC 32 Gastric 26 Prostate Best % Change in Tumor Lesion by High/ Low A 2A R levels Enrich patient population with biomarker/clinical data iTEOS independent monotherapy act
Slide 19: PORT-7: Highly Selective and Potent A2B Adenosine Receptor Antagonist
19 PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages • Activity in 4T1, CT26, and other disease models (asthma, fibrosis, sickle cell) Data on File Binding Affinity Functional Receptor Antagonism
Slide 20: ADPORT-601: Adaptive Phase 1a/1b Study
20 ADPORT - 601: Adaptive Phase 1a/1b Study * Phase 1a Starting Dose (10 mg BID) (n=12 - 15) A2AR (PORT - 6) indications: A2BR (PORT - 7) indications: Colorectal Cancer, Non - small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer, Prostate Cancer with high A2B expression Prostate Cancer, Non -
Slide 21: Strong U.S. and Global IP Positions on Platforms and Products
21 iNKT Engager • Composition, formulations with antigens, other I/O agents • Liposomes/particles 2031 - 2041 Patent Exclusivity Many Applications Pending Worldwide Strong U.S. and Global IP Positions on Platforms and Products Broad and deep intellectual property covering: >60 Issued Patents Adenosi
Slide 22: Key Upcoming Clinical Development Milestones
22 2023 2024 2025 Q3 Q4 1H 2H 1H 2H Key Upcoming Clinical Development Milestones* IMPORT - 201 (PORT - 2) Phase 2 start ADPORT - 601 (PORT - 6) First patient dosed in Phase 1a ADPORT - 601 (Port - 6) Phase 1b start IMPORT - 201 (PORT - 2) P2 PFS data *At conferences we will present multiple arms & t
Slide 23: Summary Financial Data
+ Pro forma Cash Balance is approximately $13 million, as adjusted, giving effect to $6 million financing, net of expenses, closed on October 3, 2023 (“the Financing”) * Pro forma shares of 20,944,185, as adjusted, giving effect to Financing for 3,157,895 or common stock equivalents and issuance of
Slide 24: Accelerating I/O Development in Untapped Growth Areas
24 Novel, Clinical Stage I/O Portfolio with Small Molecule Focus • Manufacturing simplicity, low capital investment • Nine potential phase 1b/2 clinical data reads over next 2 years* Engine for Efficient Drug Development & Commercialization • Expert scientific oversight • Lean structure with financi
Portage Biotech — Investor Presentation (November 2023) on 6ix